Previous Close | $80.42 |
AI Value | $248.66 |
Upside potential | +209% |
Lantheus Holdings, Inc. (LNTH) is a leading global medical technology company specializing in diagnostic imaging and precision medicine. The company develops, manufactures, and commercializes innovative diagnostic imaging agents and products that assist clinicians in the diagnosis and treatment of cardiovascular and other diseases. Lantheus' core products include DEFINITY® (a contrast agent for echocardiography), PYLARIFY® (a prostate-specific membrane antigen (PSMA)-targeted PET imaging agent), and TechneLite® (a generator used in nuclear medicine). The company holds a strong position in the diagnostic imaging market, particularly in cardiology and oncology, with a focus on improving patient outcomes through precision diagnostics. Lantheus differentiates itself through its proprietary technology platforms, strong commercial infrastructure, and strategic partnerships with leading healthcare institutions.
Lantheus invests in R&D for next-generation diagnostic imaging agents, including targeted radiopharmaceuticals. The company holds multiple patents for its proprietary technologies, including PSMA-targeted imaging.
Lantheus Holdings presents a compelling investment opportunity due to its leadership in diagnostic imaging and strong growth trajectory, particularly with PYLARIFY®. However, risks include regulatory hurdles and competitive pressures. The company's focus on innovation and strategic partnerships supports long-term potential, but investors should monitor reimbursement trends and pipeline execution.
Lantheus 10-K filings (CIK: 0001521036), investor presentations, Bloomberg market data.
Historical valuation data is not available at this time.